Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R‐MPVA) Regimen With Sequential Addition of Etoposide to R‐MPV and Ifosfamide to R‐AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study
Hematological Oncology · 2026
DOI: 10.1002/hon.70217 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Hematological Oncology, 2026. Verfasst von Gabriel Antherieu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hopital Lyon Sud, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Pierre Benite, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms, Lymphoma. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The treatment efficacy, acute toxicity, and neurocognitive sequelae of older patients with primary central nervous system lymphoma (PCNSL) remain therapeutic challenges. The standard first‐line therapy consisted of high‐dose methotrexate and cytarabine (AraC) and led to a complete response (CR) in half of the patients. To improve the response rate, we proposed intensifying the standard rituximab, methotrexate, procarbazine, vincristine, and cytarabine (R‐MPVA) regimen by sequentially adding etoposide (100 mg/m 2 D2) to R‐MPV (R‐MPV‐E) and ifosfamide (1.5 g/m 2 Days 1–3) to R‐AraC (R‐AraC‐I) for patients aged between 60 and 70 years. The primary objective of this retrospective study was to determine the CR rates after three and two planned cycles of R‐MPV‐E and R‐AraC‐I, respectively. Thirty‐two consecutive patients received this regimen between 2013 and 2021 in Lyon University Hospitals. After the R‐MPV‐E and R‐AraC‐I sequences, 11 (34.4%) and 26 (81.3%) patients achieved CR or unconfirmed CR (CRu), respectively, with favorable safety profiles (19% and 38%, of ≥ Grade 3 hematological toxicity; 19% and 27%, of ≥ Grade 3 infection during the induction and consolidation, respectively). With a median follow‐up of 42.4 months, the 3‐year event‐free survival (EFS) and overall survival (OS) rates were 40.2% and 63.2%, respectively. Historical comparisons with a subset of patients from the LOC network database revealed an improvement in CR rates of 81% after R‐MPV‐E/R‐AraC‐I versus 42.9% and 60.5% after MPVA and R‐MPVA, respectively, mainly owing to the addition of ifosfamide to the R‐AraC sequence. Similar results were observed in an independent retrospective cohort of 20 patients treated at Toulouse University‐Hospital, with a 70% CR rate after R‐MPV‐E/R‐AraC‐I. In addition, 7/26 (27%) CR/CRu patients in the main cohort could then be referred for autograft consolidation. In conclusion, this study revealed that ifosfamide combined with R‐AraC could increase the CR/CRu rate at the end of induction in 60–70‐year‐old PCNSL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Hopital Lyon Sud, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Pierre Benite, France.
- Department of Hematology, IUC CHU Toulouse, Toulouse, France.
- Department of Pathology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
- Neuro-oncology Department, Hôpital Pitié-Salpêtrière, IHU, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
- Department of Hematology, Institut Curie, Saint-cloud, France.
- Department of Hematology, Centre Leon Berard, Claude Bernard Lyon 1 University, Lyon, France.
ORCID-Profile: Gabriel Antherieu, Marie Donzel, Philippe Rey, Thiébaud Picart, Lucie Obéric, Hervé Ghesquières
Zitieren
APA
Antherieu, G., Julia, E., Lapierre, L., Donzel, M., Houillier, C., Soussain, C., Nicolas-Virelizier, E., Rey, P., Ducray, F., Meyronet, D., Picart, T., Ysebaert, L., Hoang Xuan, K., Obéric, L., & Ghesquières, H. (2026). Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R‐MPVA) Regimen With Sequential Addition of Etoposide to R‐MPV and Ifosfamide to R‐AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study. Hematological Oncology. https://doi.org/10.1002/hon.70217
Vancouver
Antherieu G, Julia E, Lapierre L, Donzel M, Houillier C, Soussain C, et al. Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R‐MPVA) Regimen With Sequential Addition of Etoposide to R‐MPV and Ifosfamide to R‐AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study. Hematological Oncology. 2026. doi:10.1002/hon.70217
BibTeX
@article{Antherieu2026,
author = {Antherieu, Gabriel and Julia, Edith and Lapierre, Léopoldine and Donzel, Marie and Houillier, Caroline and Soussain, Carole and Nicolas-Virelizier, Emmanuelle and Rey, Philippe and Ducray, François and Meyronet, David and Picart, Thiébaud and Ysebaert, Loïc and Hoang Xuan, Khê and Obéric, Lucie and Ghesquières, Hervé},
title = {Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R‐MPVA) Regimen With Sequential Addition of Etoposide to R‐MPV and Ifosfamide to R‐AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70217}
}
EUVIMED